Celdara Medical, a clinical-stage biotechnology company focused on delivering products to patients, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation, 501(c)3 non-profit organization that advances military medical research.
Celdara Medical announces the publication of new translational research in the American Journal of Transplantation indicating that a novel polymer therapeutic candidate, APP-103TM, is able to preserve kidney function in preclinical models of kidney ischemia reperfusion injury, including transplantation.
Celdara Medical, LLC today announced that the first DRIVEN Accelerator Hub Participant Company, CairnSurgical, Inc., has closed a Series A investment led by Morningside Group.
Celdara Medical, LLC and Simbex today announced the award of $250,000 in supplemental funds to the DRIVEN Accelerator Hub. The DRIVEN Accelerator Hub is an NIH-funded consortium led by Celdara Medical (therapeutics and diagnostics) and Simbex (medical devices and digital health) and includes 10 of the leading research institutions in the Northeast. The supplemental funds will be used to create the following programs:
Celdara Medical, LLC today announced the launch of an online resource database for biomedical entrepreneurs: bioentrepreneurresources.com. This database was developed by the DRIVEN Accelerator Hub, an NIH-funded consortium led by Celdara Medical including 10 of the leading research institutions in the Northeast region (NH, VT, ME, DE, and RI). The database is open to biomedical entrepreneurs globally and contains resources from across the country. New resources are added by user submission and curated by DRIVEN.
Celdara Medical, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) fast track award to fund the company’s advancement of APP-103 for the treatment of acute kidney injury (AKI). This project builds on the inventions of co-collaborator Dr. Peter Kang at the Beth Israel Deaconess Medical Center in Boston.
Celdara Medical today announced its ranking by Business NH Magazine as the fastest growing company in New Hampshire. This marks the sixth consecutive year that Celdara has ranked in the top 10, and the third consecutive year at the top of the list. Rankings are across all sectors, and are based on three-year average annual growth rate.
Celdara Medical, LLC today announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded a two-year, Small Business Innovation Research contract to fund the company’s discovery pipeline for treatment of Crohn’s Disease and other autoimmune diseases. This project will be developed in partnership with Dr. Sara Lustigman at the New York Blood Center.
Celdara Medical, LLC and The Geisel School of Medicine at Dartmouth College today announced the selection of three outstanding researchers as the recipients of the 2018 Dartmouth SYNERGY/Celdara Medical High-Potential Entrepreneurs’ Fellowships (DS-CHEF).
Celdara Medical, LLC announced today that it has received a three-year, $3.5 million award from the National Institutes of Health (NIH) to support an Institutional Development Award (IDeA) Center of Biomedical Research Excellence. Celdara Medical has been selected to create and operate a Regional Technology Transfer Accelerator Hub in the Northeast (the DRIVEN Accelerator Hub: DE, RI, VT, ME, and NH).